← All trials
NCT06743438
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Sep 30, 2029
- First posted
- Dec 19, 2024
- Last posted
- Dec 19, 2024
- Enrollment
- 640
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead sponsor
- Capital Medical UniversityOfficial
- Capital Medical UniversityOfficial
- Wenzhou Medical UniversityOfficial
- Fudan UniversityOfficial
- Fudan UniversityOfficial
- Fudan UniversityOfficial
- Central South UniversityOfficial
- Jiao Tong UniversityOfficial
- Jiao Tong UniversityOfficial
- Central South UniversityOfficial
- Xuzhou Medical UniversityOfficial
- Guangzhou Medical UniversityOfficial
- Southern Medical UniversityOfficial
- Hebei UniversityOfficial
- Hacettepe UniversityOfficial
- LanZhou UniversityOfficial
- Harbin Medical UniversityOfficial
- Nanjing UniversityOfficial
- Jinlin UniversityOfficial
- Hangzhou Xixi hospitalOfficial
- Henan Provincal People's HospitalOfficial
- Tianjin Medical UniversityOfficial
- Zunyi Medical CollegeOfficial
- Xinjiang Medical UniversityOfficial
- Sichuan UniversityOfficial
- Sichuan UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.